Successful treatment of recalcitrant juvenile pemphigus foliaceus with intravenous immunoglobulin and rituximab

Abstract

Pemphigus foliaceus (PF) is uncommon among children. The usage of rituximab in childhood PF is even less documented. We reported a case of a 16-year-old boy with juvenile PF who failed conventional treatments and was started on combination therapy of intravenous immunoglobulin (IVIG) and rituximab followed by six-monthly rituximab maintenance therapy. He achieved full remission and no adverse effects. Therefore, in cases of recalcitrant juvenile PF, combination therapy of IVIG and rituximab can be considered.